Professional Documents
Culture Documents
2018 DPRI Booklet Nov-19-18 PDF
2018 DPRI Booklet Nov-19-18 PDF
The 2018 Edition of the Drug Price Reference Index (DPRI) is a product of
hard work and dedication of the Department of Health (DOH) Pharmaceutical
Division headed by Dr. Anna Melissa S. Guerrero, team efforts of the System
Support Unit supervised by Ms. Vanessa J. Saulog – Obera, and led by Mr. Achilles
V. Aragona together with the team members namely: Mr. Jeffrey T. Castro, Ms.
Priscilla Margarette H. Alimario, Mr. Christian M. Villostas, Mr. John Lester M.
Custodio, Ms. Geny C. Belmonte, Mr. Jaldrin Ivan M. Bunag, Ms. Wilma C. Abrilla
and Mr. Christian Joel M. Tambong.
Special thanks also to all NDP Compliance Officers and EDPMS Helpdesks
who aided in the implementation of the DPRI and to the DOH-Pharmaceutical
Division family. All DOH Retained / Specialty Hospitals and Centers for Health
Development (CHDs) for contributing their data to the Department of Health.
Republic Act (RA) 9502 or the Universally Accessible Cheaper and Quality
Medicines Act of 2008 gave the DOH instruments to monitor and regulate
the prices of drugs and medicines to protect consumers and the public
procuring entities from excessive mark-ups applied to prices of medicines
resulting from information asymmetry and the lack of effective market
competition.
The DPRI lists the ceiling prices of essential medicines for government
bidding and procurement set by the DOH for all National and Local
Government Health Facilities and Government Agencies. Winning bid
prices of essential medicines within the DPRI ceiling reflect efficient and
effective procurement in the government. Their transparency and
It aims to improve the efficiency and good governance in the pricing and
procurement of medicines in the public sector through establishing a
transparent and publicly available reference price for affordable and quality
medicines. It also aims to guide the Philippine Health Insurance
Corporation (PHIC) in setting reimbursement caps for medicines both for
inpatient and outpatient services.
The DPRI only reflects the acquisition costs including landed cost,
packaging, drug content, quality assurance, manufacturing overheads and
Food and Drug Administration (FDA) fees. The DPRI excludes other
costs such as pharmacy services, preparation and storage fees, and other
reasonable pharmacy mark-ups, which are now being evaluated by the
DOH.
__________________________________
1
Douglas B, Tisocki K (2009) Public Procurement Prices of Medicines in the Philippines. Health Action International.
The reference price is set at the Median or the 50th percentile across the
range of prevailing tender prices of essential medicines for each
preparation and strength plus 10% to account for the inflation. However,
for drugs and medicines with two entries the reference price was set to
lowest plus 10% to account for the inflation.
The DPRI is updated annually. All DOH hospitals and CHDs submit a
copy of their latest Purchase Orders to the DOH Pharmaceutical Division
for annual collection and analysis of price data. The updated DPRI is based
on the procurement price data of medicines from the previous year.
__________________________________
•The Reference Price was based on the proposed list price of the pharmaceutical company upon its
inclusion in the Philippine National Formulary
__________________________________
•The Reference Price was based on the proposed list price of the pharmaceutical company upon its
inclusion in the Philippine National Formulary
__________________________________
* DOH Procurement Plus 10% Inflation
•The Reference Price was based on the proposed list price of the pharmaceutical company upon its
inclusion in the Philippine National Formulary
2018 DPRI | Sixth Edition P a g e | 31
Lowest -
Drugname 2018 DPRI
Highest
755. Valsartan 160 mg Film coated tablet 15.00 - 60.50 20.71
756. Valsartan 80 mg Film coated tablet 5.33 - 41.31 11.06
757. Vancomycin 1 g Vial 210.00 - 288.00 231.00
758. Vancomycin 500 mg Vial 97.22 - 800.00 163.47
759. Verapamil 2.5mg/ml, 2mL Ampule 126.48 - 169.24 151.35
760. Verapamil 240 mg MR Tablet 20.09 - 28.70 22.10
761. Verapamil 80 mg Tablet 30.25 - 50.13 33.28
762. Vinblastine 10 mg Vial 775.00 - 800.00 880.00
763. Vincristine (As Sulfate) 1 mg/mL, 1 mL Vial 195.00 - 350.00 248.05
764. Vincristine (As Sulfate) 1 mg/mL, 2 mL Vial 300.00 - 697.00 440.00
765. Vitamin B1 B6 B12 100 mg + 100 mg + 1 mg, 3 15.11 - 65.00 32.81
mL Ampule
766. Vitamin B1 B6 B12 100 mg + 5 mg + 50 mcg 0.67 - 3.00 1.21
Tablet
W
767. Warfarin 2.5 mg Tablet 7.50 - 11.59 10.59
768. Warfarin 5 mg Tablet 9.40 - 15.60 13.07
Z
769. Zinc 27.5 mg/mL (Equiv. to 10 mg Elemental 19.39 - 50.00 38.50
Zinc), 15 mL Oral Drops
770. Zinc 55 mg/5 mL (Equiv. to 20 mg Elemental 17.04 - 51.00 42.90
Zinc), 60 mL Syrup
771. Zolpidem 10 mg Tablet 48.02 - 64.00 70.40